🇺🇸 sumatriptan succinate/naproxen sodium in United States

20 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 20

Most-reported reactions

1. Drug Ineffective — 6 reports (30%)
2. Nausea — 3 reports (15%)
3. Headache — 2 reports (10%)
4. Pseudoporphyria — 2 reports (10%)
5. Vomiting — 2 reports (10%)
6. Angina Bullosa Haemorrhagica — 1 report (5%)
7. Blood Bilirubin Increased — 1 report (5%)
8. Colitis Microscopic — 1 report (5%)
9. Diarrhoea — 1 report (5%)
10. Dysgeusia — 1 report (5%)

Source database →

Frequently asked questions

Is sumatriptan succinate/naproxen sodium approved in United States?

sumatriptan succinate/naproxen sodium does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for sumatriptan succinate/naproxen sodium in United States?

GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.